Wagner, C
Bhm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD
Amiano P, Molina-Montes E, Molinuevo A, Huerta JM, Romaguera D, Gracia E, et al
The use of histone deacetylase inhibitors (HDACI) modulates lipid metabolism and survival pathways in DLBCL, particularly by gaining dependency on the choline pathway and PI3K signaling activation (224), which results in a decline in the antineoplastic effects of the HDACI (224)
[42] conducted a meta-analysis to evaluate the risk of malignant neoplasia after GLP-1 receptor agonist administration and reported no increase in the risk of malignant neoplasia among individuals with type 2 diabetes who received GLP-1 receptor agonist administration
Alterations in the intestinal microbiota of patients with severe and active Graves orbitopathy: a cross-sectional study